<DOC>
	<DOCNO>NCT00641641</DOCNO>
	<brief_summary>The purpose study measure decay characteristic HIV blood patient take combination anti-HIV drug , include new class anti-HIV drug , integrase inhibitor . This study explore new combination therapy reduce virus various compartment body immune system .</brief_summary>
	<brief_title>The Effect Raltegravir HIV Decay During Primary Chronic Infection</brief_title>
	<detailed_description>The study open-label study 3-years duration . This study conduct 4 study site Sydney , Australia . Sixteen participant recruit comprise 8 participant diagnose primary HIV infection ( Cohort A ) 8 individual chronic HIV infection ( Cohort B ) . All patient must antiretroviral therapy ( ART ) na√Øve commence regimen combination ART consist tenofovir disoproxil fumarate emtricitabine ( TDF/FTC ; Truvada ) plus integrase inhibitor , raltegravir . Subjects follow three year intensive quantification plasma RNA cell associate DNA viral specie .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age least 18 year . Provision write , informed consent . Screening plasma HIV RNA &gt; 10,000 copies/mL . Screening CD4+ T lymphocyte count &gt; 100 x 10^6 ) /L . No previous antiretroviral therapy . Haemoglobin &gt; 115 g/L ( female ) &gt; 130 g/L ( male ) . Absolute neutrophil count &gt; 1 x 10^9/L . Platelet count &gt; 100 x 10^9/L Serum bilirubin &lt; 1.5 x ULN . Serum alkaline phosphatase &lt; 3 X ULN . Serum aspartate aminotransferase ( AST ) &lt; 3 X ULN . Serum alanine aminotransferase ( ALT ) &lt; 3 X ULN . Creatinine clearance &gt; 50mL/min ( Creatinine clearance ( mL/min ) =140 age x weight creatinine Multiply result 1.2 men ) . Cohort A : Primary HIV infection : Documented acute early infection diagnose : Acute infection : &lt; 3 band Western Blot one : i. positive p24 antigen ii . positive proviral DNA Early infection : . Positive detuned BED ELISA result OR ii . Previously negative serology within 6 month confirm positive serology . Cohort B : Chronic HIV infection : Documented HIVinfection least 12 month duration . Pregnancy breastfeed . Receipt investigational product within 1 month study entry . Receipt follow within 6 month study entry : interferon alpha gamma oral corticosteroid ( inhaled topical corticosteroid permit ) cyclosporin alkylating agent immunosuppressive agent rifampin phenytoin phenobarbital Documented genotypic ( IAS 2007 ) resistance tenofovir emtricitabine HIV drug resistance test . Any medication contraindicate Truvada raltegravir . Significant intercurrent illness apart HIV infection viral hepatitis ( diagnose core hepatitis B antigen and/or positive hepatitis B PCR positive hepatitis C PCR ) condition opinion investigator would compromise participation study . History nontraumatic osteoporotic fracture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Viral compartment</keyword>
	<keyword>integrase inhibitor therapy</keyword>
	<keyword>viral specie</keyword>
</DOC>